Patents by Inventor Klaus Rubsamen

Klaus Rubsamen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT FUSION PROTEINS FOR PREVENTING OR TREATING ADHESIONS OF TISSUES OR ORGANS
    Publication number: 20210189368
    Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.
    Type: Application
    Filed: November 13, 2020
    Publication date: June 24, 2021
    Inventors: Klaus RÜBSAMEN, Stephan WITTE
  • Recombinant fusion proteins for preventing or treating adhesions of tissues or organs
    Patent number: 10837007
    Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: November 17, 2020
    Assignee: Akesion GmbH
    Inventors: Klaus Rübsamen, Stephan Witte
  • RECOMBINANT FUSION PROTEINS FOR PREVENTING OR TREATING ADHESIONS OF TISSUES OR ORGANS
    Publication number: 20170253864
    Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.
    Type: Application
    Filed: August 20, 2015
    Publication date: September 7, 2017
    Inventors: Klaus Rübsamen, Stephan Witte
  • Thrombin muteins as antidotes for thrombin inhibitors
    Patent number: 6060300
    Abstract: The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: May 9, 2000
    Assignee: BASF Aktiengesellschaft
    Inventors: Martin Raditsch, Thomas Friedrich, Claus Bollschweiler, Martin Schmidt, Hans Wolfgang Hoffken, Jurgen Schweden, Klaus Rubsamen